Key result
Diabetic nephropathy in T2DM linked to lower serum omentin-1 levels.
Why the study?
Diabetic nephropathy is among the most dangerous complications of type II diabetes mellitus, prompting investigation into serum omentin-1 levels in diabetic patients with and without nephropathy.
Are serum omentin-1 levels associated with diabetic nephropathy in type II diabetes patients?
Case-Control (n=90)
Are serum omentin-1 levels associated with diabetic nephropathy in type II diabetes patients?
Serum omentin-1 levels are progressively lower in type II diabetes and diabetic nephropathy, suggesting a potential role as a biomarker for this microvascular complication.
Omentin-1 may mark diabetic nephropathy in type 2 diabetes; this Level 4 case-control finding leaves open biomarker utility pending prospective validation.
Background: Type II diabetes mellitus (DM) is a disorder that is becoming increasingly prevalent worldwide. Diabetes causes many microvascular and macrovascular complications. Diabetic nephropathy (DN) is among the most dangerous complications of DM. Pathways involved in the progression of DN include oxidative stress, angiotensin II, and inflammatory processes. Omentin-1 improves insulin sensitivity by increasing insulin-dependent glucose absorption in adipose tissue cells in the visceral, subcutaneous, and liver muscles. Objective: To measure the serum omentin-1 level in type-II diabetic patients with diabetic nephropathy or without nephropathy. Subjects and Methods: This case-control involved 90 participants: 60 are type-II diabetics and 30 healthy control group. 30 of the patients have DN, and 30 have not. Each group has 15 male individuals and 15 female individuals. Results: Omentin-1 level is found to be lower in type II diabetic patients with DN than in diabetic patients without DN. Conclusion: Omentin-1 is significantly lower in type II diabetic patients with DN than in type II diabetic patients without DN, which is lower than that of healthy controls.
No takes yet. Share an insight, caveat, or question.
Eissa et al. (2025) conducted a case-control in Type II Diabetes Mellitus with and without Diabetic Nephropathy (n=90). Serum Omentin-1 level measurement vs. Diabetics without nephropathy and healthy controls was evaluated on Serum omentin-1 level. Serum omentin-1 levels were significantly lower in type II diabetic patients with diabetic nephropathy compared to those without nephropathy and healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: